

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

**High levels of antibiotic tolerance and persistence are induced by the
commercial anti-microbial triclosan**

Corey S. Westfall and Petra Anne Levin*

Department of Biology, Washington University in St. Louis, St. Louis, MO 63130, USA

*Correspondence: plevin@wustl.edu

23 **Antimicrobial tolerance and bacterial persistence are confounding factors in the treatment**
24 **of recurrent and chronic infections. Here we report that the anti-microbial triclosan**
25 **increased antibiotic tolerance up to 10,000 fold and amplified persister populations in both**
26 ***Escherichia coli* and methicillin-resistant *Staphylococcus aureus*. Triclosan-mediated**
27 **protection was dependent on the alarmone ppGpp but independent of growth rate, arguing**
28 **against a simplistic model in which slow growth is sufficient to confer antibiotic tolerance.**

29

30 The prophylactic use of antibiotics in consumer goods ranging from animal feed to personal care
31 products is widely believed to be a major contributor to the epidemic increase in antibiotic
32 resistant pathogens¹⁻³. While the inverse relationship between antibiotic use and antibiotic
33 efficacy is largely attributable to the selection of heritable traits, non-heritable traits such as
34 antibiotic tolerance and persistence are also likely to be involved⁴.

35

36 In contrast to genetically resistant bacteria, which grow in the presence of an antibiotic, tolerant
37 bacteria are able to survive antibiotic challenge for longer periods of time than their more
38 sensitive counterparts⁵. Persister cells are the small sub-set of an otherwise-sensitive population
39 (~ 1 in 10^6) that exhibit levels of tolerance sufficient to protect them from otherwise lethal
40 concentrations of antimicrobial compounds⁶. Increases in antibiotic tolerance and persistence are
41 confounding factors in the treatment of chronic *P. aeruginosa*⁷ and *S. aureus*⁸ infections and are
42 thought to contribute to the refractile nature of medically relevant biofilms. Reduced growth rate
43 is associated with increased antibiotic tolerance⁹ and is a defining trait of persister cells.

44

45 Banned from consumer soaps effective September 2017 by the US Food and Drug
46 Administration, the antimicrobial triclosan remains approved for use in products ranging from
47 toothpaste to cleansers employed in healthcare settings¹⁰. In contrast to bactericidal antibiotics,
48 which kill pathogens outright, triclosan is a bacteriostatic drug that inhibits growth by targeting
49 enoyl-acyl carrier protein reductase to interfere with early steps in fatty acid synthesis¹¹.
50
51 Based on its ability to inhibit growth, we wondered if physiologically relevant levels of triclosan
52 might provide protection against bactericidal antibiotics. To address this possibility we examined
53 the relative sensitivity of *E. coli* (MG1655) and *S. aureus* (FPR3757 an USA-300 MRSA strain)
54 cultured in minimal inhibitory concentrations (MIC) of triclosan to a panel of bactericidal
55 antibiotics. Triclosan MICs for *E. coli* and MRSA were 200 ng/mL and 100 ng/mL, respectively
56 under our growth conditions, equivalent to the urine concentration of individuals using triclosan-
57 containing consumer products^{12,13}. In all cases, triclosan was added 30 minutes prior to the
58 addition of the specified bactericidal antibiotic and both antibiotics maintained in the culture for
59 the remainder of the experiment.
60
61 We utilized two approaches to evaluate the impact of triclosan on bacterial tolerance and
62 persistence: a qualitative, end-point plating efficiency assay and a quantitative kinetic kill-curve.
63 Plating efficiency assesses relative antimicrobial tolerance and the kinetic kill-curve
64 distinguishes between changes in total antibiotic tolerance and changes in persister frequency⁴.
65
66 Triclosan had a dramatic protective effect on *E. coli* in the end point assay, increasing survival
67 by several orders of magnitude in the presence of three bactericidal antibiotics and providing

68 nearly complete protection against a fourth (Figure 1). *E. coli* treated with triclosan exhibited a
69 1000-fold increase in survival in the presence of 50 µg/mL (~5x MIC) kanamycin, an inhibitor of
70 peptide bond formation, and a 10,000-fold increase in survival in the presence of streptomycin
71 (50 µg /mL: ~2x MIC), an inhibitor of tRNA-ribosome interaction, and ciprofloxacin (100
72 ng/mL: ~3x MIC) a gyrase inhibitor. (Figure 1). Strikingly, triclosan rendered *E. coli* almost
73 completely refractile to treatment with the cell wall active antibiotic ampicillin (100 µg /mL;
74 ~10x MIC). Viable cell numbers were essentially identical in triclosan and triclosan-ampicillin
75 treated cultures at 2 hours, and 10% of cells in triclosan-ampicillin cultures were viable at 20
76 hours, suggesting triclosan qualitatively increased persister frequency.

77

78 To further assess the protective effect of Triclosan, we next performed a kinetic kill curve, in
79 which we measured colony forming units (CFU) over a 20-hour time, focusing on ciprofloxacin,
80 the broad spectrum antibiotic used to treat *E. coli* related UTIs. Consistent with the results of the
81 end point assay, triclosan substantially protected *E. coli* from ciprofloxacin-induced cell death
82 throughout the duration of the time course. Protection was particularly pronounced at the 2-hour
83 time point, where the slope of the kill curve for pre-treated cells diverges substantially from that
84 of untreated cells (Figure 2). A divergent slope is diagnostic for the presence of persister cells in
85 the pre-treated population¹³.

86

87 Persister population size was proportional to the concentration of the bacteriocidal antibiotic:
88 10% of triclosan treated cells cultured at 100 ng/mL ciprofloxacin remained viable at 2 hours,
89 while only 0.1% cultured at the more clinically relevant 1,000 ng/mL ciprofloxacin were viable
90 at the same time point. For perspective, 0.1% of the population is equivalent to 1 in 10³ cells,

91 1000-fold higher than the expected frequency of persisters in an untreated population⁴. At the 20
92 hour time point, 90,000 cells per mL were viable in 100 ng/mL ciprofloxacin and 30 cells per
93 mL in 1000ng/mL ciprofloxacin. In contrast, we observed only 20 cells/ml after 20 hours of
94 growth in 100 ng/mL ciprofloxacin alone. Cells cultured in 1,000 ng/mL ciprofloxacin alone had
95 no observable colonies (<10 cells per mL).

96
97 Remarkably, triclosan also protected MRSA cells from high concentration of the cell wall
98 inhibitor vancomycin over the course of a 20-hour experiment (Figure 2C). MRSA treated with
99 100 ng/ml of triclosan were essentially refractile to 50 ng/ml vancomycin (10x the MIC) at 4
100 hours and exhibited a viable cell count 200-times that of untreated cells at 8 hours. Although not
101 statistically significant, at 20 hours the viable cell count was several times higher in the presence
102 of both triclosan and vancomycin than vancomycin alone (360,000 +/- 200,000 cells/ml versus
103 130,000 +/- 80,000 cells/ml), consistent with induction of a persistent state.

104
105 The ability of triclosan to protect cells from bactericidal antibiotics appears to be independent of
106 its impact on bacterial growth rate. Instead, genetic data support a model in which triclosan-
107 mediated tolerance stems from accumulation of the alarmone ppGpp in response to defects in
108 fatty acid synthesis¹⁵. ppGpp has been repeatedly implicated in antibiotic tolerance and
109 persistence in several organisms including *E. coli* and *S. aureus*¹⁴⁻¹⁶. To determine the
110 contribution of ppGpp accumulation to triclosan mediated tolerance, we compared the relative
111 viability of wild type and ppGpp⁰ (*spoT::cat ΔrelA*) *E. coli* cells after 2 hours antibiotic
112 challenge in the presence or absence of triclosan. Triclosan was unable to substantially protect
113 ppGpp⁰ cells from either ampicillin or ciprofloxacin (Figure 2E). For kanamycin and

114 streptomycin, the ppGpp⁰ cells showed no viable cells after 2 hours for both the triclosan-treated
115 and untreated cells. In contrast to previous studies which relied on either carbon starvation or the
116 addition of serine hydroxamate to induce accumulation of high concentrations of ppGpp [100x
117 above baseline]¹⁶, defects in fatty acid synthesis have at best a modest impact on ppGpp
118 levels[~5x over baseline]¹⁷. Thus even relatively low levels of the alarmone appear to be
119 sufficient to protect cells from a panel of antimicrobials.

120

121 Triclosan inhibited growth in the presence and absence of the alarmone, arguing against a
122 simplistic model in which reductions in growth rate are inherently protective (Figure 2F).
123 Specifically how modest increases in [ppGpp] might confer tolerance to different antibiotics thus
124 remains an open question. We favor the idea that rather than exerting a global effect, ppGpp
125 mediates changes in individual biosynthetic pathways that render them tolerant of their cognate
126 antimicrobial. For example, ppGpp-dependent down regulation of ribosomal RNA synthesis
127 significantly curtails translation, conferring resistance to the translational inhibitors kanamycin
128 and streptomycin. Similarly, increases in [ppGpp] are reported to curtail DNA replication—both
129 elongation and initiation—providing a straightforward explanation for ppGpp-mediated
130 ciprofloxacin resistance.

131

132 Regardless of mechanism, these data highlight an unexpected and potentially important role for
133 triclosan as a contributor to antibiotic tolerance and persistence in both community and health
134 care settings. While the impact of triclosan on persistence and tolerance *in vivo* remains an open
135 question, the high concentration of the compound in the urine of individuals using triclosan-
136 containing products raises the possibility that it might interfere with treatment of bladder and

137 kidney associated infections. Along with previous work identifying a connection between
138 triclosan exposure and antibiotic resistance^{18,19}, our findings reinforce the need for substantial
139 caution—as well as consideration of unintended consequences—in evaluating the costs and
140 benefit of antimicrobial additives in consumer products.

141

142 **Methods**

143 **Materials and Strains**

144 Triclosan, ampicillin, kanamycin, streptomycin, ciprofloxacin, and vancomycin were purchased
145 from Sigma-Aldrich. Stock solutions were made in water for ampicillin (100 mg/mL),
146 kanamycin (50 mg/mL), streptomycin (100 mg/mL) and ciprofloxacin (10 mg/mL). Triclosan
147 was dissolved in ethanol (10 mg/mL), and vancomycin was dissolved in DMSO (100 mg/mL). *E.*
148 *coli* MG1655 and *S. aureus* FPR3575 were both lab strains. The ppGpp0 strain was created by
149 transducing *spoT::cat* (the kind gift of Dr. Jue D. Wang) and *relA::kan*²⁰ into MG1655 using the
150 bacteriophage P1*vir*. To test kanamycin tolerance of the ppGpp0, we first cured the kanamycin
151 cassette using pCP20, and the pCP20 plasmid was then removed through growth of multiple
152 generations at 42°C²¹. *E. coli* was grown in Luria-Bertani broth (LB) and *S. aureus* was grown
153 in tryptic soy broth (TSB). Growth temperature was 37°C for all experiments.

154

155 **Determination of Minimum Inhibitory Concentration (MIC)**

156 To determine the MIC for the panel of antibiotics utilized in this study, *E. coli* and *S. aureus*
157 were grown to OD₆₀₀ = 0.1 in LB or TSB respectively. Cells were then back-diluted 1000-fold
158 and transferred to a 96-well plate containing 2-fold dilutions of respective antibiotics and
159 cultured at 37° for 16 additional hours with vigorous shaking in a BioTek Eon plate reader. MIC

160 was calculated as the lowest antibiotic concentration preventing development of detectable
161 turbidity at OD-600.

162

163 **Assays for antibiotic Tolerance and Persistence**

164 To assay tolerance and persistence, *E. coli* and *S. aureus* were grown to an OD 600 = 0.2 in LB
165 or TSB respectively. Cells were then back-diluted into media containing triclosan at indicated
166 concentrations to an OD-600 = 0.1, cultured for an additional 30 minutes, before being
167 challenged with bactericidal antibiotics. For dot plating, 10 μ L of a 10-fold dilution series was
168 plated on antibiotic free LB-agar or TSB-agar as appropriate. For determination of colony
169 forming units (CFU), 100 μ L of a 10-fold dilution series was spread on antibiotic free LB-agar or
170 TSB-agar plates. Cells were incubated for ~12 hours at 37° prior to quantification. CFUs were
171 normalized to CFUs at t0 to correct for the ~2-fold increase in cell number in untreated cultures
172 during the 30 minute pre-treatment period. Relative persistence is defined as the CFU's of the
173 triclosan treated sample divided by the CFU's of the non-treated sample.

174

175 **Growth Curve**

176 MG1655 and MG1655 ppGpp⁰ cells were grown to an OD600=0.1-0.2 in LB before back-
177 diluting to an OD600=0.02 into LB with or without 200 ng/mL triclosan. Growth was monitored
178 every 30 minutes at OD600.

179

180 **Statistical Analysis**

181 All values are expressed as the mean \pm standard deviation of n=3 replicates. Data was analyzed
182 using a one-tailed Student's t-test. Statistical significance was determined when p<.05.

183

184

185 **Acknowledgements**

186 This work was supported by National Institutes of Health grants GM64671 to P.A.L. C.S.W was

187 supported by an Arnold O. Beckman Postdoctoral Fellowship. The authors thank Dr. Robyn

188 Klein and members of the Levin and Zaher groups for insightful suggestions and critical

189 comments on the manuscript. We are grateful to Dr. Jue Wang for the kind gift of the *spoT::cat*

190 strain.

191

192 **Author Contributions**

193 C.S.W. and P.A.L designed the experiments. C.S.W. performed the experiments. C.S.W. and


194 P.A.L. analyzed the data and prepared the manuscript.

195 **References**

- 196
- 197 1. Bell, B.G. *et al. BMC Infections Diseases* **14**, 13 (2014).
- 198 2. McEwen, S.A. & Fedorka-Cray, P.J. *Clin. Infect. Dis.* **34**, S93-106 (2002).
- 199 3. Yazdankhaha, S.P. *et al. Microb. Drug Resist.* **12**, 83-90 (2006).
- 200 4. Lewis, K. *Annu. Rev. Microbiol.* **64**, 357-372 (2010).
- 201 5. Brauner, A., Fridan, O., Gefen, O., & Balaban, N.Q. *Nat. Rev. Microbiol.* **14**, 320-330
- 202 (2016).
- 203 6. Bigger, J.W. *Lancet* **244**, 497-500 (1944).
- 204 7. Mulcahy, L.R., Burns, J.L., Lory, S., & Lewis, K. *J. Bacteriol.* **192**, 6191-6199 (2010).
- 205 8. Proctor, R.A. *et al. Clin. Infect. Dis.* **20**, 95-102 (1995).
- 206 9. Balaban, N.Q. *et al. Science* **305**, 1622-1625 (2004).
- 207 10. FDA Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug
- 208 Products for Over-the-Counter Human Use, 21 C.F.R. § 310 (2016).
- 209 11. McMurry, L.M., Oethinger, M., & Levy, S.B. *Nature* **394**, 531-532 (1998).
- 210 12. Calafat, A.M. *et al. Environ. Health Perspect.* **116**, 303-307 (2008).
- 211 13. MacIsaac, J.K. *et al. J. Occup. Environ. Med.* **56**, 834-839 (2014).
- 212 14. Nguyen, D. *et al. Science* **334**, 982-986 (2011).
- 213 15. Battesti, A. & Bouveret E. *Mol Microbiol.* **62**, 1048-1063 (2006).
- 214 16. Maisonneuve, E., Castro-Camargo M., Gerdes, K. *Cell* **154**, 1140-1150 (2013).
- 215 17. Seyfzadeh, M., Keener, J., & Nomura, M. *PNAS* **90**, 11004-8 (1993).
- 216 18. Karatzas K.A. *et al. J. Antimicrob. Chemother.* **60**, 947-955 (2007).
- 217 19. Webber, M.A., Randall, L.P., Cooles, S., Woodward, M.J., Piddock L.J. *J. Antimicrob.*
- 218 *Chemother.* **62**, 83-91 (2008).
- 219 20. Baba T. *et al. Mol. Syst. Biol.* **2**, 2006.0008 (2006).
- 220 21. Cherepanov, P.P. & Wackernagel W. *Gene* **156**, 9-14 (1995).
- 221
- 222
- 223
- 224
- 225
- 226
- 227
- 228
- 229
- 230
- 231

232

233 **Figures**



234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249 **Figure 1: Triclosan induces tolerance to multiple antibiotics.** *E. coli* (MG1655) were cultured

250 to OD₆₀₀ = 0.2, split and cultured for an additional 30 minutes with (+T) or without 200ng/ml


251 triclosan (-T). Indicated bactericidal antibiotics were then added and cells cultured for an

252 additional 2 to 20 hours prior to dilution plating. Each experiment was replicated three

253 independent times with only representative data shown.

254

255



256

257

258 **Figure 2: Kinetic analysis of triclosan-induced persistence.** *E. coli* (MG1655) and MRSA

259 (FPR3757) cells were cultured to OD600 = 0.2, split and cultured for an additional 30 minutes

260 with (black line, closed squares) or without triclosan (grey line, open squares). At $t=0$, 100
261 ng/mL (A) or 1 $\mu\text{g/mL}$ ciprofloxacin (B) was added to *E. coli* cultures and 50ng/ml vancomycin
262 was added to MRSA cultures (C). Relative persistence in the presence of triclosan
263 (CFU+T/CFU-T) was calculated for the 4 and 20 hour time points (D). Cell viability of ppGpp⁰
264 *E. coli* with (+T) or without (-T) pretreatment with triclosan after 2 hour challenge with
265 ampicillin or vancomycin (E). Growth curves of MG1655 (black curve) or ppGpp⁰ (gray curve)
266 in LB with (dashed lines) or without (solid lines) triclosan (F). Values are the mean of three
267 independent biological replicates with error bars indicating one standard deviation. Asterisks
268 represent significant difference between the triclosan treated and non-treated using a Student's t-
269 test with $p < 0.05$.